US2007270344A1PendingUtilityA1
Compositions and methods for treating ophthalmic disorders
Est. expiryMar 16, 2026(expired)· nominal 20-yr term from priority
Inventors:Pierre Belichard
A61P 43/00A61P 27/00A61P 29/00A61P 27/02C07K 16/40A61K 38/57A61K 47/30C07K 2317/55A61K 9/0048A61K 2039/505
41
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The present invention relates to compositions and methods for treating ophthalmic disorders of humans or animals. The present compositions and methods are highly suitable for intraocular administration into the interior of an eye and provide therapeutic effects to the eye as they are effective in stabilizing, enhancing and/or improving a patient's vision. More specifically, the present invention relates to compositions and methods for treating ophthalmic diseases or disorders with exudative, hemorrhagic and/or inflammatory conditions. Even more specifically, the present invention relates to compositions and methods for treating retinal diseases or disorders, and more specifically ophthalmic diseases or disorders related to impaired retinal vessel permeability and/or integrity.
Claims
exact text as granted — not AI-modified1 : A method inhibits serine protease for the preparation of an ophthalmic composition useful for the treatment of ophthalmic disorders in a patient in need thereof comprising utilizing at least one peptide that inhibits serine protease.
2 : The method of claim 1 , wherein said peptide is a kallikrein inhibitor.
3 : The method of claim 1 , wherein said peptide is a Kunitz domain polypeptide.
4 : The method of claim 1 , wherein said peptide includes the amino acid sequence: Xaa1 Xaa2 Xaa3 Xaa4 Cys Xaa6 Xaa7 Xaa8 Xaa9 Xaa10 Xaa11 Gly Xaa13 Cys Xaa15 Xaa16 Xaa17 Xaa18 Xaa19 Xaa20 Xaa21 Xaa22 Xaa23 Xaa24 Xaa25 Xaa26 Xaa27 Xaa28 Xaa29 Cys Xaa31 Xaa32 Phe Xaa34 Xaa35 Gly Gly Cys Xaa39 Xaa40 Xaa41 Xaa42 Xaa43 Xaa44 Xaa45 Xaa46 Xaa47 Xaa48 Xaa49 Xaa50 Cys Xaa52 Xaa53 Xaa54 Cys Xaa56 Xaa57 Xaa58 (SEQ ID NO:1) with Xaa s being, independently from one another, any amino acid.
5 : The method of claim 4 , wherein one or more of the following apply:
Xaa1, Xaa2, Xaa3, Xaa4, Xaa56, Xaa57 or Xaa58 are, independently from one another, any amino acid or absent; Xaa10 is an amino acid selected from the group consisting of Asp and Glu; Xaa11 is an amino acid selected from the group consisting of Asp, Gly, Ser, Val, Asn, lie, Ala and Thr; Xaa13 is an amino acid selected from the group consisting of Arg, His, Pro, Asn, Ser, Thr, Ala, Gly, Lys and Gln; Xaa15 is an amino acid selected from the group consisting of Arg, Lys, Ala, Ser, Gly, Met, Asn and Gln; Xaa16 is an amino acid selected from the group consisting of Ala, Gly, Ser, Asp and Asn; Xaa17 is an amino acid selected from the group consisting of Ala, Asn, Ser, Ile, Gly, Val, Gln and Thr; Xaa18 is an amino acid selected from the group consisting of His, Leu, Gln and Ala; Xaa19 is an amino acid selected from the group consisting of Pro, Gln, Leu, Asn and Ile; Xaa21 is an amino acid selected from the group consisting of Trp, Phe, Tyr, His and Ile; Xaa22 is an amino acid selected from the group consisting of Tyr and Phe; Xaa23 is an amino acid selected from the group consisting of Tyr and Phe; Xaa31 is an amino acid selected from the group consisting of Glu, Asp, Gln, Asn, Ser, Ala, Val, Leu, Ile and Thr; Xaa32 is an amino acid selected from the group consisting of Glu, Gln, Asp Asn, Pro, Thr, Leu, Ser, Ala, Gly and Val; Xaa34 is an amino acid selected from the group consisting of Thr, Ile, Ser, Val, Ala, Asn, Gly and Leu; Xaa35 is an amino acid selected from the group consisting of Tyr, Trp and Phe; Xaa39 is an amino acid selected from the group consisting of Glu, Gly, Ala, Ser and Asp; Xaa40 is an amino acid selected from the group consisting of Gly and Ala; Xaa43 is an amino acid selected from the group consisting of Asn and Gly; Xaa45 is an amino acid selected from the group consisting of Phe and Tyr; Xaa6, Xaa7, Xaa8, Xaa9, Xaa20, Xaa24, Xaa25, Xaa26, Xaa27, Xaa28, Xaa29, Xaa41, Xaa42, Xaa44, Xaa46, Xaa47, Xaa48, Xaa49, Xaa50, Xaa52, Xaa53 and Xaa54 are, independently from one another, any amino acid.
6 : The method of claim 1 , wherein said peptide is selected in the group consisting of:
(SEQ ID NO:2)
Met His Ser Phe Cys Ala Phe Lys Ala Asp Asp Gly
Pro Cys Arg Ala Ala His Pro Arg Trp Phe Phe Asn
Ile Phe Thr Arg Gln Cys Glu Glu Phe Ile Tyr Gly
Gly Cys Glu Gly Asn Gln Asn Arg Phe Glu Ser Leu
Glu Glu Cys Lys Lys Met Cys Thr Arg Asp,
(SEQ ID NO:3)
Met His Ser Phe Cys Ala Phe Lys Ala Xaa10 Xaa11
Gly Xaa13 Cys Xaa15 Xaa16 Xaa17 Xaa18 Xaa19 Arg
Xaa21 Phe Phe Asn Ile Phe Thr Arg Gln Cys Xaa31
Xaa32 Phe Xaa34 Xaa35 Gly Gly Cys Xaa39 Gly Asn
Gln Asn Arg Phe Glu Ser Leu Glu Glu Cys Lys Lys
Met Cys Thr Arg Asp,
(SEQ ID NO:4)
Met His Ser Phe Cys Ala Phe Lys Ala Asp Asp Gly
Pro Cys Lys Ala Asn His Leu Arg Phe Phe Phe Asn
Ile Phe Thr Arg Gln Cys Glu Glu Phe Ser Tyr Gly
Gly Cys Gly Gly Asn Gln Asn Arg Phe Glu Ser Leu
Glu Glu Cys Lys Lys Met Cys Thr Arg Asp,
(SEQ ID NO:5)
Met His Ser Phe Cys Ala Phe Lys Ala Asp Asp Gly
His Cys Lys Ala Asn His Gln Arg Phe Phe Phe Asn
Ile Phe Thr Arg Gln Cys Glu Glu Phe Thr Tyr Gly
Gly Cys Gly Gly Asn Gln Asn Arg Phe Glu Ser Leu
Glu Glu Cys Lys Lys Met Cys Thr Arg Asp,
(SEQ ID NO:6)
Met His Ser Phe Cys Ala Phe Lys Ala Asp Asp Gly
His Cys Lys Ala Asn His Gln Arg Phe Phe Phe Asn
Ile Phe Thr Arg Gln Cys Glu Gln Phe Thr Tyr Gly
Gly Cys Ala Gly Asn Gln Asn Arg Phe Glu Ser Leu
Glu Glu Cys Lys Lys Met Cys Thr Arg Asp,
(SEQ ID NO:7)
Met His Ser Phe Cys Ala Phe Lys Ala Asp Asp Gly
His Cys Lys Ala Ser Leu Pro Arg Phe Phe Phe Asn
Ile Phe Thr Arg Gln Cys Glu Glu Phe Ile Tyr Gly
Gly Cys Gly Gly Asn Gln Asn Arg Phe Glu Ser Leu
Glu Glu Cys Lys Lys Met Cys Thr Arg Asp,
(SEQ ID NO:8)
Met His Ser Phe Cys Ala Phe Lys Ala Asp Asp Gly
His Cys Lys Ala Asn His Gln Arg Phe Phe Phe Asn
Ile Phe Thr Arg Gln Cys Glu Glu Phe Ser Tyr Gly
Gly Cys Gly Gly Asn Gln Asn Arg Phe Glu Ser Leu
Glu Glu Cys Lys Lys Met Cys Thr Arg Asp,
(SEQ ID NO:9)
Met His Ser Phe Cys Ala Phe Lys Ala Asp Asp Gly
His Cys Lys Gly Ala His Leu Arg Phe Phe Phe Asn
Ile Phe Thr Arg Gln Cys Glu Glu Phe Ile Tyr Gly
Gly Cys Glu Gly Asn Gln Asn Arg Phe Glu Ser Leu
Glu Glu Cys Lys Lys Met Cys Thr Arg Asp,
(SEQ ID NO:10)
Met His Ser Phe Cys Ala Phe Lys Ala Asp Asp Gly
Arg Cys Lys Gly Ala His Leu Arg Phe Phe Phe Asn
Ile Phe Thr Arg Gln Cys Glu Glu Phe Ile Tyr Gly
Gly Cys Glu Gly Asn Gln Asn Arg Phe Glu Ser Leu
Glu Glu Cys Lys Lys Met Cys Thr Arg Asp,
(SEQ ID NO:11)
Met His Ser Phe Cys Ala Phe Lys Ala Asp Gly Gly
Arg Cys Arg Gly Ala His Pro Arg Trp Phe Phe Asn
Ile Phe Thr Arg Gln Cys Glu Glu Phe Ser Tyr Gly
Gly Cys Gly Gly Asn Gln Asn Arg Phe Glu Ser Leu
Glu Glu Cys Lys Lys Met Cys Thr Arg Asp,
(SEQ ID NO:12)
Met His Ser Phe Cys Ala Phe Lys Ala Asp Asp Gly
Pro Cys Arg Ala Ala His Pro Arg Trp Phe Phe Asn
Ile Phe Thr Arg Gln Cys Glu Glu Phe Ser Tyr Gly
Gly Cys Gly Gly Asn Gln Asn Arg Phe Glu Ser Leu
Glu Glu Cys Lys Lys Met Cys Thr Arg Asp,
(SEQ ID NO:13)
Met His Ser Phe Cys Ala Phe Lys Ala Asp Val Gly
Arg Cys Arg Gly Ala His Pro Arg Trp Phe Phe Asn
Ile Phe Thr Arg Gln Cys Glu Glu Phe Ser Tyr Gly
Gly Cys Gly Gly Asn Gln Asn Arg Phe Glu Ser Leu
Glu Glu Cys Lys Lys Met Cys Thr Arg Asp,
(SEQ ID NO:14)
Met His Ser Phe Cys Ala Phe Lys Ala Asp Val Gly
Arg Cys Arg Gly Ala Gln Pro Arg Phe Phe Phe Asn
Ile Phe Thr Arg Gln Cys Glu Glu Phe Ser Tyr Gly
Gly Cys Gly Gly Asn Gln Asn Arg Phe Glu Ser Leu
Glu Glu Cys Lys Lys Met Cys Thr Arg Asp,
(SEQ ID NO:15)
Met His Ser Phe Cys Ala Phe Lys Ala Asp Asp Gly
Ser Cys Arg Ala Ala His Leu Arg Trp Phe Phe Asn
Ile Phe Thr Arg Gln Cys Glu Glu Phe Ser Tyr Gly
Gly Cys Gly Gly Asn Gln Asn Arg Phe Glu Ser Leu
Glu Glu Cys Lys Lys Met Cys Thr Arg Asp,
(SEQ ID NO:16)
Met His Ser Phe Cys Ala Phe Lys Ala Glu Gly Gly
Ser Cys Arg Ala Ala His Gln Arg Trp Phe Phe Asn
Ile Phe Thr Arg Gln Cys Glu Glu Phe Ser Tyr Gly
Gly Cys Gly Gly Asn Gln Asn Arg Phe Glu Ser Leu
Glu Glu Cys Lys Lys Met Cys Thr Arg Asp,
(SEQ ID NO:17)
Met His Ser Phe Cys Ala Phe Lys Ala Asp Asp Gly
Pro Cys Arg Gly Ala His Leu Arg Phe Phe Phe Asn
Ile Phe Thr Arg Gln Cys Glu Glu Phe Ser Tyr Gly
Gly Cys Gly Gly Asn Gln Asn Arg Phe Glu Ser Leu
Glu Glu Cys Lys Lys Met Cys Thr Arg Asp,
(SEQ ID NO:18)
Met His Ser Phe Cys Ala Phe Lys Ala Asp Asp Gly
His Cys Arg Gly Ala Leu Pro Arg Trp Phe Phe Asn
Ile Phe Thr Arg Gln Cys Glu Glu Phe Ser Tyr Gly
Gly Cys Gly Gly Asn Gln Asn Arg Phe Glu Ser Leu
Glu Glu Cys Lys Lys Met Cys Thr Arg Asp,
(SEQ ID NO:19)
Met His Ser Phe Cys Ala Phe Lys Ala Asp Ser Gly
Asn Cys Arg Gly Asn Leu Pro Arg Phe Phe Phe Asn
Ile Phe Thr Arg Gln Cys Glu Glu Phe Ser Tyr Gly
Gly Cys Gly Gly Asn Gln Asn Arg Phe Glu Ser Leu
Glu Glu Cys Lys Lys Met Cys Thr Arg Asp,
(SEQ ID NO:20)
Met His Ser Phe Cys Ala Phe Lys Ala Asp Ser Gly
Arg Cys Arg Gly Asn His Gln Arg Phe Phe Phe Asn
Ile Phe Thr Arg Gln Cys Glu Glu Phe Ser Tyr Gly
Gly Cys Gly Gly Asn Gln Asn Arg Phe Glu Ser Leu
Glu Glu Cys Lys Lys Met Cys Thr Arg Asp,
(SEQ ID NO:21)
Met His Ser Phe Cys Ala Phe Lys Ala Asp Gly Gly
Arg Cys Arg Ala Ile Gln Pro Arg Trp Phe Phe Asn
Ile Phe Thr Arg Gln Cys Glu Glu Phe Ser Tyr Gly
Gly Cys Gly Gly Asn Gln Asn Arg Phe Glu Ser Leu
Glu Glu Cys Lys Lys Met Cys Thr Arg Asp,
(SEQ ID NO:22)
Met His Ser Phe Cys Ala Phe Lys Ala Asp Asp Gly
Arg Cys Arg Gly Ala His Pro Arg Trp Phe Phe Asn
Ile Phe Thr Arg Gln Cys Glu Glu Phe Ser Tyr Gly
Gly Cys Gly Gly Asn Gln Asn Arg Phe Glu Ser Leu
Glu Glu Cys Lys Lys Met Cys Thr Arg Asp.
(SEQ ID NO:23)
Glu Ala Met His Ser Phe Cys Ala Phe Lys Ala Asp
Asp Gly Pro Cys Arg Ala Ala His Pro Arg Trp Phe
Phe Asn Ile Phe Thr Arg Gln Cys Glu Glu Phe Ile
Tyr Gly Gly Cys Glu Gly Asn Gln Asn Arg Phe Glu
Ser Leu Glu Glu Cys Lys Lys Met Cys Thr Arg Asp,
(SEQ ID NO:24)
Glu Ala Met His Ser Phe Cys Ala Phe Lys Ala Xaa10
Xaa11 Gly Xaa13 Cys Xaa15 Xaa16 Xaa17 Xaa18 Xaa19
Arg Xaa21 Phe Phe Asn Ile Phe Thr Arg Gln Cys
Xaa31 Xaa32 Phe Xaa34 Xaa35 Gly Gly Cys Xaa39 Gly
Asn Gln Asn Arg Phe Glu Ser Leu Glu Glu Cys Lys
Lys Met Cys Thr Arg Asp,
(SEQ ID NO:25)
Glu Ala Met His Ser Phe Cys Ala Phe Lys Ala Asp
Asp Gly Pro Cys Lys Ala Asn His Leu Arg Phe Phe
Phe Asn Ile Phe Thr Arg Gln Cys Glu Glu Phe Ser
Tyr Gly Gly Cys Gly Gly Asn Gln Asn Arg Phe Glu
Ser Leu Glu Glu Cys Lys Lys Met Cys Thr Arg Asp,
(SEQ ID NO:26)
Glu Ala Met His Ser Phe Cys Ala Phe Lys Ala Asp
Asp Gly His Cys Lys Ala Asn His Gln Arg Phe Phe
Phe Asn Ile Phe Thr Arg Gln Cys Glu Glu Phe Thr
Tyr Gly Gly Cys Gly Gly Asn Gln Asn Arg Phe Glu
Ser Leu Glu Glu Cys Lys Lys Met Cys Thr Arg Asp,
(SEQ ID NO:27)
Glu Ala Met His Ser Phe Cys Ala Phe Lys Ala Asp
Asp Gly His Cys Lys Ala Asn His Gln Arg Phe Phe
Phe Asn Ile Phe Thr Arg Gln Cys Glu Gln Phe Thr
Tyr Gly Gly Cys Ala Gly Asn Gln Asn Arg Phe Glu
Ser Leu Glu Glu Cys Lys Lys Met Cys Thr Arg Asp,
(SEQ ID NO:28)
Glu Ala Met His Ser Phe Cys Ala Phe Lys Ala Asp
Asp Gly His Cys Lys Ala Ser Leu Pro Arg Phe Phe
Phe Asn Ile Phe Thr Arg Gln Cys Glu Glu Phe Ile
Tyr Gly Gly Cys Gly Gly Asn Gln Asn Arg Phe Glu
Ser Leu Glu Glu Cys Lys Lys Met Cys Thr Arg Asp,
(SEQ ID NO:29)
Glu Ala Met His Ser Phe Cys Ala Phe Lys Ala Asp
Asp Gly His Cys Lys Ala Asn His Gln Arg Phe Phe
Phe Asn Ile Phe Thr Arg Gln Cys Glu Glu Phe Ser
Tyr Gly Gly Cys Gly Gly Asn Gln Asn Arg Phe Glu
Ser Leu Glu Glu Cys Lys Lys Met Cys Thr Arg Asp,
(SEQ ID NO:30)
Glu Ala Met His Ser Phe Cys Ala Phe Lys Ala Asp
Asp Gly His Cys Lys Gly Ala His Leu Arg Phe Phe
Phe Asn Ile Phe Thr Arg Gln Cys Glu Glu Phe Ile
Tyr Gly Gly Cys Glu Gly Asn Gln Asn Arg Phe Glu
Ser Leu Glu Glu Cys Lys Lys Met Cys Thr Arg Asp,
(SEQ ID NO:31)
Glu Ala Met His Ser Phe Cys Ala Phe Lys Ala Asp
Asp Gly Arg Cys Lys Gly Ala His Leu Arg Phe Phe
Phe Asn Ile Phe Thr Arg Gln Cys Glu Glu Phe Ile
Tyr Gly Gly Cys Glu Gly Asn Gln Asn Arg Phe Glu
Ser Leu Glu Glu Cys Lys Lys Met Cys Thr Arg Asp,
(SEQ ID NO:32)
Glu Ala Met His Ser Phe Cys Ala Phe Lys Ala Asp
Gly Gly Arg Cys Arg Gly Ala His Pro Arg Trp Phe
Phe Asn Ile Phe Thr Arg Gln Cys Glu Glu Phe Ser
Tyr Gly Gly Cys Gly Gly Asn Gln Asn Arg Phe Glu
Ser Leu Glu Glu Cys Lys Lys Met Cys Thr Arg Asp,
(SEQ ID NO:33)
Glu Ala Met His Ser Phe Cys Ala Phe Lys Ala Asp
Asp Gly Pro Cys Arg Ala Ala His Pro Arg Trp Phe
Phe Asn Ile Phe Thr Arg Gln Cys Glu Glu Phe Ser
Tyr Gly Gly Cys Gly Gly Asn Gln Asn Arg Phe Glu
Ser Leu Glu Glu Cys Lys Lys Met Cys Thr Arg Asp,
(SEQ ID NO:34)
Glu Ala Met His Ser Phe Cys Ala Phe Lys Ala Asp
Val Gly Arg Cys Arg Gly Ala His Pro Arg Trp Phe
Phe Asn Ile Phe Thr Arg Gln Cys Glu Glu Phe Ser
Tyr Gly Gly Cys Gly Gly Asn Gln Asn Arg Phe Glu
Ser Leu Glu Glu Cys Lys Lys Met Cys Thr Arg Asp,
(SEQ ID NO:35)
Glu Ala Met His Ser Phe Cys Ala Phe Lys Ala Asp
Val Gly Arg Cys Arg Gly Ala Gln Pro Arg Phe Phe
Phe Asn Ile Phe Thr Arg Gln Cys Glu Glu Phe Ser
Tyr Gly Gly Cys Gly Gly Asn Gln Asn Arg Phe Glu
Ser Leu Glu Glu Cys Lys Lys Met Cys Thr Arg Asp,
(SEQ ID NO:36)
Glu Ala Met His Ser Phe Cys Ala Phe Lys Ala Asp
Asp Gly Ser Cys Arg Ala Ala His Leu Arg Trp Phe
Phe Asn Ile Phe Thr Arg Gln Cys Glu Glu Phe Ser
Tyr Gly Gly Cys Gly Gly Asn Gln Asn Arg Phe Glu
Ser Leu Glu Glu Cys Lys Lys Met Cys Thr Arg Asp,
(SEQ ID NO:37)
Glu Ala Met His Ser Phe Cys Ala Phe Lys Ala Glu
Gly Gly Ser Cys Arg Ala Ala His Gln Arg Trp Phe
Phe Asn Ile Phe Thr Arg Gln Cys Glu Glu Phe Ser
Tyr Gly Gly Cys Gly Gly Asn Gln Asn Arg Phe Glu
Ser Leu Glu Glu Cys Lys Lys Met Cys Thr Arg Asp,
(SEQ ID NO:38)
Glu Ala Met His Ser Phe Cys Ala Phe Lys Ala Asp
Asp Gly Pro Cys Arg Gly Ala His Leu Arg Phe Phe
Phe Asn Ile Phe Thr Arg Gln Cys Glu Glu Phe Ser
Tyr Gly Gly Cys Gly Gly Asn Gln Asn Arg Phe Glu
Ser Leu Glu Glu Cys Lys Lys Met Cys Thr Arg Asp,
(SEQ ID NO:39)
Glu Ala Met His Ser Phe Cys Ala Phe Lys Ala Asp
Asp Gly His Cys Arg Gly Ala Leu Pro Arg Trp Phe
Phe Asn Ile Phe Thr Arg Gln Cys Glu Glu Phe Ser
Tyr Gly Gly Cys Gly Gly Asn Gln Asn Arg Phe Glu
Ser Leu Glu Glu Cys Lys Lys Met Cys Thr Arg Asp,
(SEQ ID NO:40)
Glu Ala Met His Ser Phe Cys Ala Phe Lys Ala Asp
Ser Gly Asn Cys Arg Gly Asn Leu Pro Arg Phe Phe
Phe Asn Ile Phe Thr Arg Gln Cys Glu Glu Phe Ser
Tyr Gly Gly Cys Gly Gly Asn Gln Asn Arg Phe Glu
Ser Leu Glu Glu Cys Lys Lys Met Cys Thr Arg Asp,
(SEQ ID NO:41)
Glu Ala Met His Ser Phe Cys Ala Phe Lys Ala Asp
Ser Gly Arg Cys Arg Gly Asn His Gln Arg Phe Phe
Phe Asn Ile Phe Thr Arg Gln Cys Glu Glu Phe Ser
Tyr Gly Gly Cys Gly Gly Asn Gln Asn Arg Phe Glu
Ser Leu Glu Glu Cys Lys Lys Met Cys Thr Arg Asp,
(SEQ ID NO:42)
Glu Ala Met His Ser Phe Cys Ala Phe Lys Ala Asp
Gly Gly Arg Cys Arg Ala Ile Gln Pro Arg Trp Phe
Phe Asn Ile Phe Thr Arg Gln Cys Glu Glu Phe Ser
Tyr Gly Gly Cys Gly Gly Asn Gln Asn Arg Phe Glu
Ser Leu Glu Glu Cys Lys Lys Met Cys Thr Arg Asp,
(SEQ ID NO:43)
Glu Ala Met His Ser Phe Cys Ala Phe Lys Ala Asp
Asp Gly Arg Cys Arg Gly Ala His Pro Arg Trp Phe
Phe Asn Ile Phe Thr Arg Gln Cys Glu Glu Phe Ser
Tyr Gly Gly Cys Gly Gly Asn Gln Asn Arg Phe Glu
Ser Leu Glu Glu Cys Lys Lys Met Cys Thr Arg Asp.
7 : The method of claim 1 , wherein said peptide is Glu Ala Met His Ser Phe Cys Ala Phe Lys Ala Asp Asp Gly Pro Cys Arg Ala Ala His Pro Arg Trp Phe Phe Asn Ile Phe Thr Arg Gln Cys Glu Glu Phe Ile Tyr Gly Gly Cys Glu Gly Asn Gln Asn Arg Phe Glu Ser Leu Glu Glu Cys Lys Lys Met Cys Thr Arg Asp (SEQ ID NO:23).
8 : The method of claim 1 , wherein said ophthalmic disorder is an exudative and/or inflammatory ophthalmic disorder.
9 : The method of claim 1 , wherein said ophthalmic disorder is related to impaired retinal vessel permeability and/or integrity.
10 : The method of claim 1 , wherein said ophthalmic disorder is a back of the eye disease.Join the waitlist — get patent alerts
Track US2007270344A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.